Agreements

OctoPlus has signed a feasibility agreement with a leading US-based pharmaceutical company, aimed at developing a controlled release formulation of the client's therapeutic compound for local delivery into joints. The contract covers initial activities in developing a controlled release formulation of an undisclosed compound using Octoplus's proprietary drug delivery technology PolyActive^®. If the evaluation is successful, the project may progress into a full development, manufacturing and licensing agreement.